Spectinomycin Discontinued as Treatment for Gonorrhea

Ceftriaxone is the only remaining alternative treatment for quinolone-resistant gonorrhea in the U.S.

According to a new CDC report, Pfizer has discontinued distribution of spectinomycin (Trobicin) in the U.S. This drug was previously recommended for the treatment of gonorrhea in three select groups with penicillin or cephalosporin allergies: (1) pregnant women, (2) patients in areas with a high prevalence of quinolone-resistant Neisseria gonorrhoeae, and (3) men who have sex with men (MSM). Spectinomycin was effective for treating urogenital and anorectal gonorrhea but not for pharyngeal gonorrhea. The drug continues to be distributed outside the U.S.

Comment

During the past several years, alternative treatments for gonorrhea have gradually disappeared. First, in 2002, Wyeth discontinued the distribution of cefixime tablets i…

Reviewing Author

Carlos del Rio, MD

Spectinomycin Discontinued as Treatment for Gonorrhea

Topics

Comment

Reviewing Author